Shots:

• Janssen to present new data from the fixed-duration cohort of P-II CAPTIVATE study- demonstrating 95% of patients treated with combined Imbruvica + Venetoclax were alive and progression-free @2yrs. with deep remissions were seen across all subgroups- including patients with high-risk CLL
• Additionally- Janssen will present 7yrs. data from the RESONATE-2 study on PFS and OS benefits with single-agent Imbruvica- reinforcing the survival benefits and long-term tolerability of therapy for patients with CLL
• The results of RESONATE-2 study supporting the long-term benefits of Imbruvica monothx. in 1L CLL- supporting the use of Imbruvica as SOC

  Ref: Janssen | Image: Janssen